Your browser doesn't support javascript.
loading
Anti-CD20 therapies for pediatric-onset multiple sclerosis: A systematic review.
Etemadifar, Masoud; Nouri, Hosein; Sedaghat, Nahad; Ramezani, Aryana; Kargaran, Parisa K; Salari, Mehri; Kaveyee, Hasan.
Afiliación
  • Etemadifar M; Department of Neurosurgery, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
  • Nouri H; School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran; Network of Immunity in Infection, Malignancy, and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Isfahan, Iran.
  • Sedaghat N; School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran; Network of Immunity in Infection, Malignancy, and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Isfahan, Iran.
  • Ramezani A; School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
  • Kargaran PK; Department of Cardiovascular Medicine, Center for Regenerative Medicine, Mayo Clinic, Rochester, Rochester, MN, USA.
  • Salari M; Functional Neurosurgery Research Center, Shohada Tajrish Comprehensive Neurosurgical Center of Excellence, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  • Kaveyee H; School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran. Electronic address: kaveyeehasan@gmail.com.
Mult Scler Relat Disord ; 91: 105849, 2024 Nov.
Article en En | MEDLINE | ID: mdl-39243503
ABSTRACT

BACKGROUND:

Pediatric-onset multiple sclerosis (POMS) cases, defined as multiple sclerosis (MS) with onset before the age of 18, represent between 3 and 5 % of all MS patients. Anti-CD20 drugs mainly rituximab, ocrelizumab, and ofatumumab are being widely used in adult-onset MS. Their use in POMS is also being increasingly considered by experts.

OBJECTIVE:

to review the latest evidence on safety and efficacy of the use of anti-CD20 therapies in POMS.

METHODS:

An extensive search was performed in PubMed, Scopus, and Web of Science databases until the end of July 1st, 2024. Two independent reviewers screened the articles, and collected data. 832 studies were screened using Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines.

RESULTS:

12 studies on rituximab (328 patients) and 6 studies on ocrelizumab (106 patients) were synthesized. Using monoclonal antibodies in POMS patients has a noteworthy effect on reducing relapses and lesions and achieving no evidence of disease activity especially in highly active POMS patients. However, anti-CD20 therapies in MS are associated with potential adverse events (AEs). Additional data is required on the effect of anti-CD20 therapy on disability accrual.

CONCLUSION:

Although anti-CD20 therapy is associated with some AEs, it can be provided in several circumstances, especially to patients with highly active disease, or ones resistant to platform therapies.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Antígenos CD20 / Rituximab / Factores Inmunológicos / Esclerosis Múltiple Límite: Child / Humans Idioma: En Revista: Mult Scler Relat Disord Año: 2024 Tipo del documento: Article País de afiliación: Irán Pais de publicación: Países Bajos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Antígenos CD20 / Rituximab / Factores Inmunológicos / Esclerosis Múltiple Límite: Child / Humans Idioma: En Revista: Mult Scler Relat Disord Año: 2024 Tipo del documento: Article País de afiliación: Irán Pais de publicación: Países Bajos